Employees department of Public Health

Dr. I. Lansdorp-Vogelaar PhD - click to enlarge
Dr. I. Lansdorp-Vogelaar PhD
Associate Professor
Biography Research Interests Projects Publications Working papers Memberships Contact

    Selected Publications

    Optimizing CRC screening strategies  

    1. Peterse EFP, …, Lansdorp-Vogelaar I. The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: Microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline. Cancer. 2018 May 30. doi: 10.1002/cncr.31543.

    2. Knudsen AB, Zauber AG, Rutter CM, Naber SK, Doria-Rose VP, Pabiniak C, Johanson C, Fischer SE, Lansdorp-Vogelaar I*, Kuntz KM*. Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force. JAMA. 2016 Jun 21;315(23):2595-609.

    3. Toes-Zoutendijk E, van Leerdam ME, …, Lansdorp-Vogelaar I; Dutch national colorectal cancer screening working group. Real-Time Monitoring of Results During First Year of Dutch Colorectal Cancer Screening Program and Optimization by Altering Fecal Immunochemical Test Cut-off Levels. Gastroenterology. 2016

    4. Van Hees F, Zauber AG, van Veldhuizen H, Heijnen MA, Penning C, de Koning HJ, van Ballegooijen M, Lansdorp-Vogelaar I. The value of models in informing resource allocation in colorectal cancer screening: the case of the Netherlands. Gut 2015 10.1136/gutjnl-2015-309316

    5. van der Steen A, Knudsen AB, van Hees F, Walter GP, Berger FG, Daguise VG, Kuntz KM, Zauber AG, van Ballegooijen M, Lansdorp-Vogelaar I. Optimal Colorectal Cancer Screening in States' Low-Income, Uninsured Populations-The Case of South Carolina. Health Serv Res. 2015 Jun;50(3):768-89.


    Targeted colorectal cancer screening and surveillance strategies

    1. Meester RGS, …, Lansdorp-Vogelaar I. Optimizing colorectal cancer screening by race and sex: Microsimulation analysis II to inform the American Cancer Society colorectal cancer screening guideline. Cancer. 2018 May 30. doi: 10.1002/cncr.31542.

    2. Gini A, …, Lansdorp-Vogelaar I. Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer. Gastroenterology. 2018 Feb;154(3):556-567

    3. Naber SK, …, Lansdorp-Vogelaar I. Cost Effectiveness of Age-Specific Screening Intervals for People With Family Histories of Colorectal Cancer. Gastroenterology. 2018 Jan;154(1):105-116.e20

    4. van Heijningen EM, Lansdorp-Vogelaar I, van Hees F, Kuipers EJ, Biermann K, de Koning HJ, van Ballegooijen M, Steyerberg EW; SAP Study Group. Developing a score chart to improve risk stratification of patients with colorectal adenoma. Endoscopy. 2016 Jun;48(6):563-70.

    5. Lansdorp-Vogelaar, I, Gulati R, Mariotto AB, Schechter CB, de Carvalho TM, Knudsen AB, van Ravesteyn NT, Heijnsdijk EA, Pabiniak C, van Ballegooijen M, Rutter CM, Kuntz KM, Feuer EJ, Etzioni R, de Koning HJ, Zauber AG, Mandelblatt JS. Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. Ann Intern Med. 2014; 161(2): 104-1 


    Explaining trends and disparities in CRC incidence and mortality

    1. Meester RG, Doubeni CA, Zauber AG, Goede SL, Levin TR, Corley DA, Jemal A, Lansdorp-Vogelaar I. Public health impact of achieving 80% colorectal cancer screening rates in the United States by 2018. Cancer. 2015 Mar 12. doi: 10.1002/cncr.29336.
    2. Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, van Ballegooijen M, Zauber AG, Jemal A. Contribution of screening and survival differences to racial disparities in colorectal cancer rates. CEBP 2012; 21(5):728-36.
    3. Naishadham D, Lansdorp-Vogelaar I, Siegel R, Cokkinides V, Jemal A. State Disparities in Colorectal Cancer Mortality Patterns in the United States. CEBP, 2011;20(7):1296-302.
    4. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, van Ballegooijen M, Goede SL, Ries LA. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116(3):544-73.  

    Surveillance of trends in esophageal adenocarcinoma (EAC)

    1. Heberle CR, Omidvari AH, Ali A, Kroep S, Kong CY, Inadomi JM, Rubenstein JH, Tramontano AC, Dowling EC, Hazelton WD, Luebeck EG, Lansdorp-Vogelaar I, Hur C. Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device. Clin Gastroenterol Hepatol. 2017 Sep;15(9):1397-1404

    2. Kroep S, Lansdorp-Vogelaar I, Rubenstein JH, de Koning HJ, Meester R, Inadomi JM, van Ballegooijen M. An Accurate Cancer Incidence In Barrett's Esophagus: A Best Estimate Using Published Data And Modeling. Gastroenterology. 2015 Apr 29. pii: S0016-5085(15)00601-0

    3. Kroep S, Lansdorp-Vogelaar I, van der Steen A, Inadomi JM, van Ballegooijen M. The Impact of Uncertainty in Barrett's Esophagus Progression Rates on Hypothetical Screening and Treatment Decisions. Med Decis Making. 2014 Oct 2. pii: 0272989X14551640

    4. Kroep S, Lansdorp-Vogelaar I, Rubenstein JH, Lemmens VE, van Heijningen EB, Aragonés N, van Ballegooijen M, Inadomi JM. Comparing trends in esophageal adenocarcinoma incidence and lifestyle factors between the United States, Spain, and the Netherlands. Am J Gastroenterol. 2014 Mar;109(3):336-43

    Model development, validity and transparency  

    1. van der Steen A, van Rosmalen J, Kroep S, van Hees F, Steyerberg EW, de Koning HJ, van Ballegooijen M, Lansdorp-Vogelaar I. Calibrating Parameters for Microsimulation Disease Models: A Review and Comparison of Different Goodness-of-Fit Criteria. Med Decis Making. 2016 Jul;36(5):652-65
    2.  Rutter CM, Knudsen AB, Marsh TL, Doria-Rose VP, Johnson E, Pabiniak C, Kuntz KM, van Ballegooijen M, Zauber AG, Lansdorp-Vogelaar I. Validation of Models Used to Inform Colorectal Cancer Screening Guidelines: Accuracy and Implications. Med Decis Making. 2016 Jan 8. pii: 0272989X15622642.
    3. Lansdorp-Vogelaar I, M van Ballegooijen, R Boer, AG Zauber, JDF Habbema. A novel Hypothesis on the Sensitivity of FOBT – Results of a Joint Analysis of Three Randomized Controlled Trials. Cancer 2009;115(11):2410-9

    Click here for a complete list of publications